Xin Qiu
Statistician/clinical biostatistics researcher at Johnson & Johnson (Janssen Research & Development)
Data updated
Papers
Trials
Research Footprint
Xin Qiu appears in 5 tracked papers (2020–2025), most studied alongside Esketamine and Ketamine, across Depressive Disorders, Suicidality and Major Depressive Disorder (MDD).
Most-cited paper: Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) (407 citations).
Frequent co-authors: Daniel Fu, Robert Lane and Carla Maria Canuso.
Background & Research
Xin Qiu is a biostatistics professional at Johnson & Johnson/Janssen Research & Development, where he has coauthored multiple clinical trial publications on esketamine for major depressive disorder, treatment-resistant depression, and suicidal ideation. He also appears as a coauthor on a paper analyzing recreational psychedelic users’ mystical experiences and wellbeing, suggesting broader involvement in mental health and psychedelic-related research. Based on the available evidence, this appears to be a statistical or clinical research role rather than a faculty appointment.
Key Impact
He is a coauthor on multiple esketamine trials spanning treatment-resistant depression and suicidal ideation, contributing biostatistical expertise to key psychedelic-adjacent psychiatric research.
Collaboration Network
7 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Xin Qiu is associated with.